October 01, 2019
Update on progress in clinical lead program VP01 (C21)
Media
October 01, 2019
GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext
October 01, 2019
Nordic Nanovector appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs
September 26, 2019
Patient recruitment in the Pivotal Phase 2-Study HORIZON completed
September 25, 2019
Strongbridge Biopharma plc to Present at the 2019 Cantor Global Healthcare Conference
September 24, 2019
Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
September 23, 2019
GenSight Biologics reports sustained efficacy and safety at 96 weeks in RESCUE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
September 19, 2019
Strongbridge Biopharma plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published in The Lancet Diabetes & Endocrinology
September 18, 2019
BONESUPPORT HOLDING AB presents health economic evidence
September 17, 2019
Nordic Nanovector R&D Day unveils updates on several programs